 | |
| Clinical data | |
|---|---|
| Other names | Ro 16-0154 |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H14123IN3O3 |
| Molar mass | 407.290 g/mol |
| 3D model (JSmol) | |
| |
| |
Iomazenil (also known asRo16-0154,INN,USAN;benzodine) is anantagonist and partialinverse agonist ofbenzodiazepine and a potential treatment foralcohol use disorder. The compound was introduced in 1989 by pharmaceutical companyHoffmann-La Roche as anIodine-123-labelledSPECT tracer for imaging benzodiazepine receptors (GABAA receptors) in the brain. Iomazenil is an analogue offlumazenil (Ro15-1788).[1]
123I-labelled iomazenil can be used to imageepileptic seizure foci as an alternative to18F-fludeoxyglucosePET imaging.[2][3]
The effect of iomazenil of reducing levels ofGABA in the brain was used by researchers to exacerbate symptoms in patients withschizophrenia in a laboratory study, supporting the theory that a GABA deficiency underlies that disease.[4]
Researchers atYale University andVeterans Affairs Connecticut Healthcare System have been testing iomazenil as a potential treatment fordrunkenness due to its ability to bind alcohol receptors in the brain.[5]
{{cite book}}:|work= ignored (help)